SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

$SNPX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $SNPX alert in real time by email
SC 13G/A 1 tm233830d1_sc13ga.htm SC 13G/A

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED

PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO

FILED PURSUANT TO RULE 13d-2

 

(Amendment No. 4)*

 

Synaptogenix, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value

(Title of Class of Securities)

 

234652419

(CUSIP Number)

 

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)
xRule 13d-1(c)
¨Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 234652419 13G Page 2 of 5

  

         
1.   NAMES OF REPORTING PERSONS

George W. Haywood
   
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)  ¨
(b)  ¨
   
3.   SEC USE ONLY
 
   
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
   

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
 
0
  6.   SHARED VOTING POWER
 
0
  7.   SOLE DISPOSITIVE POWER
 
0
  8.   SHARED DISPOSITIVE POWER
 
0

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0
   
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨
   
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%
   
12.   TYPE OF REPORTING PERSON (see instructions)

IN
   
         

 

 

 

 

CUSIP No. 234652419 13G Page 3 of 5

 

Item 1.

 

  (a) Name of Issuer
Synaptogenix, Inc.
     
  (b) Address of Issuer’s Principal Executive Offices
1185 Avenue of the Americas, 3rd Floor, New York, NY 10036
     

Item 2.

 

  (a) Name of Person Filing
George W. Haywood
     
  (b) Address of the Principal Office or, if None, Residence
c/o Moomjian, Waite & Coleman, LLP, 350 Jericho Turnpike, Suite 104, Jericho, New York 11753
     
  (c) Citizenship
United States
     
  (d) Title of Class of Securities
Common Stock, par value 0.0001 per share
     
  (e) CUSIP Number
234652419

 

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
  (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
  (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
  (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

 

 

 

CUSIP No. 234652419 13G Page 4 of 5

 

 

Item 4.  Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned:   0
       
(b) Percent of class:     0%
       
(c) Number of shares as to which the person has:    
       
  (i) Sole power to vote or to direct the vote: 0
       
  (ii) Shared power to vote or to direct the vote: 0
       
  (iii) Sole power to dispose or to direct the disposition of: 0
       
  (iv) Shared power to dispose or to direct the disposition of: 0

 

Item 5.  Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

 

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not applicable. 

 

Item 8.  Identification and Classification of Members of the Group.

 

 Not applicable.

 

Item 9.  Notice of Dissolution of Group.

 

 Not applicable.

 

Item 10.  Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11.

 

 

 

 

CUSIP No. 234652419 13G Page 5 of 5

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

January18, 2023

Date

 

 

/s/ George W. Haywood

Signature

 

 

George W. Haywood

Name/Title

 

 

 

 

Get the next $SNPX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SNPX

DatePrice TargetRatingAnalyst
More analyst ratings

$SNPX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

    $19.6 million in cash and cash equivalents as of September 30, 2024 Dramatically reduced cash burn rate expected NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding. "Synaptogenix

    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Synaptogenix Announces $5.0 Million Financing

    NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "Registered Offering") and a concurrent private placement (the "Private Placement" and collectively with the Registered

    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

    Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK, July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issu

    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNPX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SNPX
SEC Filings

See more

$SNPX
Leadership Updates

Live Leadership Updates

See more
  • Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

    Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Develo

    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

    Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the International Association of Biomedical Sciences for his presentation at the University of Southern California-sponsored IABS Forum-2023, a gathering of world-renowned neuroscientists and academics discussing "New Concepts for the Treatment of Neurodegenerative

    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Oblong Appoints Two New Directors to its Board

    Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SNPX
Financials

Live finance-specific insights

See more
  • Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

    Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK, July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer's disease (AD).  The SAB is comprised of industry and academic leaders in science and drug development and will be instrumental in the further development of the Company's regenerative therapies across AD, Fragile X syndrome,

    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Synaptogenix Announces Corporate Update Conference Call

    NEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will also take live Q&A following their prepared remarks. The U.S. toll free dial-in for the conference call is (877) 407-8293, and the international dial-in number is 1-(201) 689-8349. Fo

    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

    NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A Regenerative Therapeutic Strategy." "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients.  Analyses of treatment benefit, based on mean differences and as a function of successive dosing in

    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNPX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more